Basilea Pharmaceutica (Switzerland)

Recent papers from Basilea Pharmaceutica (Switzerland)

1. A pivotal Phase 2 study of derazantinib for previously-treated, locally advanced or metastatic cholangiocarcinoma with FGFR2 aberrations: FIDES-01Hepatology · 2026
2. No clinically relevant QTc prolongation with ceftibuten or ledaborbactam etzadroxil: concentration-QTc analyses from two phase I studiesJournal of Antimicrobial Chemotherapy · 2026
3. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trialThe Lancet · 2015
4. Pharmacokinetics, safety, and tolerability of ceftibuten-ledaborbactam etzadroxil in participants with renal impairmentAntimicrobial Agents and Chemotherapy · 2026
5. Complicated urinary tract infections: evolving definitions, clinical burden, and treatment landscape amid antimicrobial resistanceExpert Review of Anti-infective Therapy · 2026
6. How to Replace the TQT Study—The Use of Concentration‐QTc Modeling to Exclude a Small Effect of a Novel Drug on QT Interval: Historical Perspective and ImplementationThe Journal of Clinical Pharmacology · 2026
7. Xenobiotic Hazards in Aircraft Cabin AirJournal of Xenobiotics · 2026
8. Plasma and intrapulmonary pharmacokinetics of ceftibuten and ledaborbactam in healthy male and female adultsAntimicrobial Agents and Chemotherapy · 2026
9. In Vitro Antimicrobial Activity of Ceftobiprole and Comparator Agents Against Streptococcus pneumoniae Responsible for Lower Respiratory Tract Infections in the United States (2016–2020), Including Resistant Subsets and Select SerotypesAntibiotics · 2026
10. In vitro activity of ceftobiprole against Gram-positive clinical bacterial isolates causing skin and skin structure infections in the United StatesDiagnostic Microbiology and Infectious Disease · 2026
11. Myelin Basic Protein Post-Translational Modifications Orchestrate Astrocyte Regulatory NetworksNeuroSci · 2026
12. Optical Waveguide Lightmode Spectroscopy: A Versatile Technique for Real-Time, Label-Free BiosensingSensors · 2026
13. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Ceftobiprole Continuous Infusion Dosing Regimens for Patients with Staphylococcus aureus Bacteremia (SAB)Open Forum Infectious Diseases · 2026
14. Pharmacokinetic modeling and efficacy of ceftobiprole medocaril against pneumonic tularemia in cynomolgus macaquesAntimicrobial Agents and Chemotherapy · 2025
15. Ceftobiprole versus ceftriaxone ± linezolid in Community-Acquired Bacterial Pneumonia (CABP): Re-analysis of a randomized, phase 3 study using 2020 FDA guidanceSHILAP Revista de lepidopterología · 2025
16. Discovery and optimization of oxidative phosphorylation inhibitors from a phenotypic screenAnti-Cancer Drugs · 2025
17. Predicting the Hydration of Ground Granulated Blast Furnace Slag and Recycled Glass Blended CementsSHILAP Revista de lepidopterología · 2025
18. A phase 1/2a dose-finding study and biomarker assessment of oral lisavanbulin in patients with high-grade glioma or glioblastomaCell Reports Medicine · 2025
19. Aerotoxic Syndrome—Susceptibility and RecoveryToxics · 2025
20. Impact of obesity on clinical outcomes in patients treated with ceftobiprole: results from Phase 3 clinical trialsJournal of Antimicrobial Chemotherapy · 2025